EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary
September 12, 2024
Earnings Call Speaker Segments
Nicola Fiore
unknownGood afternoon, everyone, and welcome to the conference call on EL.En.'s financial results for Half year 2024. This call is being recorded today. There will also be a chance to ask questions at the end of the call. Joining me are Andrea Cangioli, El.En 's CEO, and Enrico Romagnoli, EL.En's Cheif Financial Officer and Investor Relator. Before we start, please be aware that the remarks management makes on this call regarding future expectations, plans and prospects are forward-looking statements. Some statements on this call, including those concerning the company's beliefs, plans, objectives, estimates or expectations of possible future results or events, constitute forward-looking statements. Forward-looking statements carry known or new risks, including general economic and business conditions and conditions in the industry we operate in, and may be affected if our assumptions prove inaccurate. Considerably, no forward-looking statements can be guaranteed, and actual future results, performance or achievements may differ materially from those addressed or implied by such forward-looking statements. The company undertakes no obligation regarding the content nor to update the forward-looking statements to reflect events or circumstances arising after the trade here of. <<operator_script>> At this time, I will give the floor to Andrea Cangioli.
Nicola Fiore
unknownAndrea, you have the floor.
Andrea Cangioli
executiveThanks, Nicola. Thanks to Polytems for the introduction, and thanks to all of you for being with us on this call following the release of the 6-month financials report. As of June 30, 2024, I'll walk through the main themes of the 6 months, and after that I'll hand things over to Enrico Romagnoli for the financial details. The fact -- the first half of 2024 ended with group revenues a bit above EUR 312 million, roughly 9% behind the equivalent period of 2023. EBIT for the 6 months also came down, to EUR 34.1 million, 12% lower than 2023, but it was strong on EBIT margin, which held very solid at close to 11%. A onetime event added EUR 5 million to income before taxes and took net income to an excellent EUR 27.4 million (sic) EUR 27.3 million, beating 2023 on this metric. We had noted in the original annual guidance release and in the update that came later that results were expected to decline initially and then recover during the year, on both revenues and EBIT. We knew we were in for a weak start because of the slower order intake momentum in the second half of 2023.
Andrea Cangioli
executiveBut the order intake and overall customer movement were also getting better in the opening months of the year, which pointed to an improvement in how we were performing starting in the second quarter. That projection came true only in part. The Medical sector performed well in Q2, posting results in line with the same period in 2023, for both revenue and profit. Even though the first 6 months were not favorable in Italy, trends across the European markets were quite positive. Revenues in the rest of the world were slightly down, hit by a weak start to the year in the American and Middle Eastern markets, especially when set against the very positive trend of the first half of 2023. However, the difficulties in the Industrial sector, especially in Cutting, which caused a decline in revenue and profit results across the entire industrial sector and consequently in the consolidated results, were not overcome in the 6 months. All in all, the 6 months revenues results stayed slightly below the schedule for meeting the annual guidance. While in terms of EBIT, the strong performance of the second quarter brought the 6 months EBIT in line with the expected performance for the year. Given the overall market situation, we are quite pleased with these results.
Andrea Cangioli
executiveActually, during the first six months of 2024, market conditions were less favorable than they had been previously. GDP is declining in relevant countries such as Germany, which along with others is being affected by the ongoing international tensions arising from the wars in Ukraine and the Middle East, as well as by high interest rates and by uncertainty over the possible impact of the ecological transition on certain manufacturing activities. Those factors weakened demand across several significant markets. Italy's industrial sector was severely penalized by a sharp and widespread drop in demand, caused not only by the general situation but also by the latency phase of investment incentivation policies for industrial equipment. The 5.0 incentive, meant to replace the highly effective 4.0 incentives that expired with 2023, was announced but never put in place, adding to demand that was already weak and was suffering from the obvious anticipation driven in 2023 by the expected end of the 4.0, plus a tendency to procrastinate on investments based on expectations about the new tax policy. Hopefully, this very weak phase was overcome in the summer, when the guidelines for the 5.0 tax incentives were published. The Chinese market continued to suffer from a structural crisis, with manufacturers equipped and organized to benefit from unexpected growth in demand forced to aggressively reduce pricing on the domestic market, which is not growing as expected, and increasingly turning to export to compensate for the weak domestic demand.
Andrea Cangioli
executiveWhen it comes to static medical applications, demand from the American market—the most important one globally—is not holding at the levels seen in prior years. Revenues fell sharply for our reporting competitors in the U.S. market. By that I mean the competitors that are listed and have publicly released their results. Even so, the group confirmed and strengthened its standing among the leaders in several application segments. It is recognized as a leader in the international markets where it operates. The innovative processes that let us improve our product range and offer customers attractive, cutting-edge solutions remain central to the group's activities, strategic focus and investments. Our innovative processes' effectiveness has allowed the group to capture the growth opportunities the market presents, and will continue to do so. Primary urology, aesthetic medicine and identification markets posted excellent performances during the period. For example, Lasit, our company based in Torre Annunziata near Naples, which controls 4 subsidiaries in Poland, Germany, Spain and the U.K., recorded a 10% revenue increase and a 22% EBIT increase in the 6 months, despite a very unfavorable situation in the Italian machine tools market. Beyond the general trends of the main application segments, I'd like to use this call to share some additional detail with you regarding application trends.
Andrea Cangioli
executiveWhen it comes to Aesthetics, we keep posting strong revenue numbers in our biggest application area, hair removal, and that figure is low, which means a drop versus what we saw a year ago. Making up for that drop is the superb reception in the market for our anti-aging platforms rage. The group offers something no one else does, with multiple distinct technologies on hand for different ways of addressing anti-aging requirements. And every one of those technologies carries deeply innovative content in the systems we have just brought out. Ablative CO2 systems, for instance Tetra Pro by DEKA, are focused on facial rejuvenation using minimally invasive methods such as Coolpeel, and that is doing well in the U.S. In the Alter store pools application, Nano and Picoseconds, such as the Discovery PICO by Quanta and TORO, just launched by DEKA, serve as the standard of care for toning and perform very well across Far East markets. The non-ablative technology of RedTouch Pro by DEKA is ushering in a fresh paradigm for regenerative medicine treatments. Facial firming and reshaping now find in the microwave technology of Onda and Onda Pro by DEKA a superb tool, on top of the well-known body shaping and cellulite removal capabilities of that system. Innovation within the hair removal segment, through Echo and Suprema by Quanta System and Motus Pro by DEKA, is designed to drive a recovery in the hair segment too.
Andrea Cangioli
executiveWhen it comes to surgical use, Quanta System brought out a new product — the Magneto, or Magneto System, for urology — and that's a breakthrough supporting the strong market position we still hold in this application segment. Being able to modulate energetic laser pulses from high-power lasers without pushing the stone away from the fiber tip, through a kind of magnetic attraction, which is what the system's name suggests, ultimately allows the device's effectiveness to rise. Over the course of the semester, the group carried on with its sustainability-related activities, and those are among the performance metrics tied to management compensation — sorry. Under the 5-year plan covering 2023-2027, the group pinpointed specific, measurable sustainability activities and objectives across all the sensitive teams involved, such as tackling climate change, the circular economy, promoting our responsible supply chain, valuing people and contributing to the community. That reaffirms its continuing commitment to sustainable development and shows that environmental and social responsibility are ever more integral to the group's business model. On cash generation, the 6 months performance essentially matched expectations, with cash generated by operations absorbed by a modest increase in net working capital and by the dividend payment. And the net financial position under accounting standards rose as an effect of nonrecurring inflows from the liquidity investment we book in long-term assets.
Andrea Cangioli
executiveCapEx has also been proceeding to date in line with the plans. The rise in net working capital that we registered over the 6 months, while revenue was declining, is due to ordinary and seasonal effects and seasonal factors. Inventories generally tend to go up in the first half because of our programming cycle, which is designed to make sure we are set to cover the planned needs and some potential upside. Just a note: without planning our components availability to cover potential upside, we would never be able to manage our sales volume upside. In this 2024, there has been no upside to date. In fact, we're a little short in meeting the planned revenue targets, very short in some areas. Therefore, we have some extra parts for the 6 months plan and the parts needed for the expected recovery in Q3 and Q4. By the end of the year, usually, this misalignment is readjusted -- it gets readjusted and absorbed. As for the laser cutting division, the project to realize an IPO on a regulated market in China, which had already been suspended in 2023 due to inadequate financial results for a successful IPO and due to the weakness of the Chinese market. The process is now interrupted.
Andrea Cangioli
executiveWe don’t observe short-term market trends that would make a successful listing of the division supportable. Having canceled the IPO process, we are now carrying out a reorganization of the laser cutting division’s activities. Cutlite Penta, which had been moved under the control of Penta Laser Zhejiang in 2019 so the division’s IPO could proceed while preventing possible horizontal competition, was repurchased on August 29, 2024, by Atlas, a subsidiary 98% controlled by EL.En. Under this new setup, there is no longer a need for the financial investor to be present in Penta Laser Zhejiang’s shareholder base. Penta Laser Zhejiang went ahead and liquidated the position of the private equity funds that had invested in its capital under the terms of the original capital increase agreement, paying those investors their investment capital plus interest of 6% per year. To avoid any potential dispute from the investment fund CITIC, even though CITIC had previously waived its right to exercise withdrawal options in the absence of an IPO, we considered it prudent to proceed with its liquidation as well. We briefly reported these events in the half year report as significant events that occurred after the end of the period covered by the report.
Andrea Cangioli
executiveAs usual, the full details are going to come in the third-quarter report, which is scheduled for release in the middle of November. Please, Enrico, go ahead with your part.
Enrico Romagnoli
executiveThank you, Andrea. Good morning, everyone. And as usual, I'll give a quick run-through of the H1 financial results. For the first half of 2024, the group posted revenues of EUR 312.9 million, a decrease of 9.5% compared to the corresponding period of 2023. Sales fell more in the Industrial sector during the period, minus 19.9%, than in the Medical sector, minus 1.7%. Industrial sector sales as a share of group sales went from 42.6% in 2023 down to 37.7% in the first half of 2024. In the first 6 months of 2024, weakness in the Renminbi in the Industrial sector and the Yen in the Medical sector, again, the Euro, had a cumulative impact on growth of roughly minus 0.8%, in value minus EUR 2.7 million — minus EUR 1.8 million from the Renminbi, minus EUR 0.8 million from the Yen. Gross margin for the first half of 2024 came in at EUR 129 million, down 2% from the EUR 133.5 million (sic) EUR 131.5 million on June 2023, with sales margins recovering from 38% to 41.2%. The gross margin improvement is due to EUR 1.9 million, equal to 0.6 percentage points of turnover, from the proceeds for insurance and government reimbursement relating to the damage caused by the flood in <<inaudible>> in November 2023.
Enrico Romagnoli
executiveAfter subtracting those proceeds, the margin for the period was still 2.5 percentage points better than in the first half of 2023. That came from a more favorable mix of sales — both by product type and by destination markets within each individual sector — and from the greater relative weight of the medical sector. Operating expenses rose, and their impact on sales went from 8.9% to 10%. The primary driver is sales and marketing expenses for trade first and Congress, incurred by both the Medical and Industrial companies. The group took part in a significant, above-average number of international trade fairs and conferences during the first month of the year. Staff costs rose in value from EUR 0.8 million, plus 1.5%, and their impact on sales went from 16% to 17.9% because of the lower turnover recorded in the period. The national cost for stock option plans in favorable employees came to EUR 1.3 million in the period, versus EUR 1.6 million in the first half 2023. As of June, the group had 2,030 employees, down from 2,082 employees as of December 2023, with the main decrease in Chinese companies. EBITDA was EUR 41.4 million, down 9.3% from EUR 45.7 million in the first half 2023.
Enrico Romagnoli
executiveThe revenue impact is still 13.2%, with a modest gain in Q2. Depreciation and provisions cost rose to EUR 7.2 million from EUR 6.7 million, and their effect on turnover went from 2% to 2.3%. This higher cost line came about because of a bigger provision for credit risks — both the general one and, above all, the specific provision of EUR 1.6 million that we had to set aside after the abrupt financial crisis of a major customer of our Japanese subsidiaries. Thanks to a less unfavorable warranty arrangement on laser cutting system sales in China, we were able to partially release the product warranty fund, while the risk provision came down after Asclepion resolved several disputes positively. EBIT was positive at EUR 34.2 million, 12% lower than the EUR 38.9 million as of June 2023, with the margin on sales essentially flat at 10.9%. We posted a net financial loss of EUR 468,000 versus the EUR 1 million loss in the same period of the prior financial year. That improvement stems mainly from more favorable currency exchange rate effects during the period. Pre-tax income was positive at EUR 38.5 million, compared with EUR 37.8 million in the first half of 2023.
Enrico Romagnoli
executiveTo reiterate what Andrea said earlier, the private equity funds’ departure from Penta Zhejiang’s capital has made it clear that the company’s IPO on the Chinese market cannot be completed. Under the terms of the contract through which the group bought the Penta Zhejiang shares held by the JV’s minority partner in 2019, listing by November 2024 was the condition for paying a EUR 5 million earn-out to the liquidated partner. Management, applying the IFRS 9 standard, has therefore remeasured the financial liability, recognizing EUR 5 million in non-operating other income in profit and loss. The overall tax rate for the period is 28.7%, a slight decrease from 29.1% in the first half of 2023, and net income came to EUR 27.3 million. On the balance sheet, we saw a decline in non-current assets, mainly because of the disposal of the -- a partial disposal during Q2 of the mid- to long-term liquidity investment in insurance policy, at a fair value of EUR 16.3 million. The ratio of net working capital to sales rose in the first 6 months versus year-end, as usual, and shows the same value as of June 2023.
Enrico Romagnoli
executiveOur net financial position rose to EUR 68.6 million as of June 2024, up from EUR 54.6 million at the close of 23. On cash flow, the net financial position posted a EUR 14 million gain over the period. That entire increase came in the second quarter, which alone delivered a balance improvement of EUR 22.5 million. Income flow from operating activities, along with depreciation and the allowance for the first half of 2024, came to more than EUR 30 million, and those funds went toward a EUR 14 million rise in net working capital and other receivables and payables, a EUR 17 million dividend, and EUR 8 million of CapEx. The partial disposal of the investment in liquidity I mentioned earlier -- back when we were discussing the net financial position -- contributed a positive EUR 16.3 million to the net financial position, and the residual fair value of that investment, still carried among non-current assets, stands at EUR 7.5 million. The remeasurement of the financial debt tied to the anticipated expiry of the earn-out clause -- which had required Atlas to pay EUR 5 million to the former partner of the Chinese JV should Penta Laser Zhejiang complete its IPO by the end of 2024 -- had a favorable effect of EUR 5 million on the net financial position, since that sum had been recorded as a financial liability in the prior financial statements.
Enrico Romagnoli
executiveTurning to sales by business. Medical sector sales as a share of group sales rose from 57% to 62% during the first half of 2024. Medical sector sales performed well in Q2 2024, rising 1.6% versus Q2 2023 and trimming the decline for the 6 months 2024 to roughly 2%. Industrial sales moved the opposite way, with a 27% increase in Q2 compared to Q2 2023, whereas in Q1 there had been a 10% decrease. That decrease is mainly due to the cutting division, which posted a minus 34% in Q2, up 14% -- minus 14% in the Q1. System sales in the Medical sector declined slightly, fairly consistently across the various application segments, aesthetic surgery and therapy. Revenue for services per parts and consumables, on the other hand, grew 6%, limiting the overall decline in the Medical sector to 2%, a commendable result given the market situation despite marking a decline of 3% in seminal revenue. The aesthetics segment delivered an excellent result in the second quarter, plus 6.5%, recovering ground compared to 2023, thanks to significant revenue growth in the anti-aging technologies. Revenue for surgical systems showed a slight decline, but this revenue, a consumable referring to the box included in this category are accounted in the service, and a strong contribution to the aftersales service has been made by the optical fiber, with that representing more or less the 40% of the sales of this kind of the aftersales service sales.
Enrico Romagnoli
executiveThe therapy segment, managed within the group by ASA <<inaudible>>, posted revenue of EUR 7.7 million, reflecting a slight revenue decline for the quarter — minus 5% versus the EUR 8.1 million recorded in the same period in 2023. In the industrial application sector, sales were hurt by weak performance in the main outbound markets, especially China and Italy, where unfavorable general conditions were compounded by a latency phase in the tax incentives policy for investment, mainly in Italy. There was, however, an extraordinary acceleration in revenue from aftersales service and goods, up 45%. That is a direct and delayed consequence of the significant increase in the number of systems installed over the last 2 years, with the share of service revenue on total sector revenue doubling during the period from 5% to around 10%. The market sector, with a turnover of EUR 13 million compared to EUR 14.5 million in the same period 2023, recorded a decline of 10%, with a weak semester integration application also due to widespread difficulty in the period in the fashion system. And growth came for the business unit of identification and traceability system managed by Lasit of Torre Annunziata. The laser sources segment reported good sales performance, plus 5%, with revenue of EUR 2.3 million.
Enrico Romagnoli
executiveLooking at where sales came from geographically during the first half of 2024, Italy’s market showed clear softness: revenue fell 46% in the Industrial sector and 9% in the Medical sector. In Industrial, the impact came from the tax benefit under incentive 4.0 ending, combined with the lengthy delay before the new 5.0 incentive arrived. Europe delivered positive results in both Medical and Industrial. Slightly lower revenue elsewhere in the world reflected continued weakness in China’s metal cutting laser system market as well as a slow start to the year in the American and Middle Eastern markets. Andrea, over to you to discuss the guidance.
Andrea Cangioli
executiveThank you, Rico. Before I finish this presentation and move into the Q&A portion, I want to revisit the guidance. The results for the first half of 2024 showed a decline compared to the corresponding figure of 2023 — a decline that the 2024 guidance had anticipated for the first months of the financial year. Considering how current revenues are performing in light of current market conditions, the volumes of order backlog to date, and the group's competitive position in the Medical and Industrial sectors, we do not foresee in the second half of the year a full recovery of the revenues delay with respect to 2023. Nevertheless, thanks to a different and more favorable revenue mix with more weight on Medical sales — and, within the Industrial sector, with more weight on international sales, meaning outside Italy and outside China, as an effect of our international expansion strategies — the goal of exceeding in 2024 the consolidated EBIT of 2023 is conferred. Moreover, the group is confident that the medium-term performance of our outbound markets will continue to outline positive developments. And thanks to our commitment to supporting continuing and focused investments in research and development and innovation to improve our competitiveness over time, we expect to benefit from the growth opportunities of our markets.
Andrea Cangioli
executiveThanks. That wraps up our remarks, and we’re ready to take your questions, if you have any.
Bianca Fersini-Mastelloni
unknownAndrea, there are 3 people on the Q&A list. The first is Giovanni Selvetti from Berenberg.
Giovanni Selvetti
analystHi, everybody. Is my audio coming through okay?
Enrico Romagnoli
executiveGiovanni, yep — we’ve got you loud and clear.
Giovanni Selvetti
analystI've got a couple of questions, and I hope some of them are very short answer. So the first one: I was looking at Industrial revenues, and the Industrial revenues generated in Europe are up 40% in the second quarter. I was wondering whether, by trying to compensate for this weakness in Italy by selling abroad in Europe, the margins you can make abroad with exports are higher than what you can do domestically. Secondly, staying on Industrial. You said during the presentation that finally, the guidelines about Industry 5.0 were out in the summer. I know that summer in Italy is quite peculiar. So it's going to take a while to see an impact, but I was wondering if you have a first sense on -- in September about the first days, if you see some practical implication of this. The third is probably more strategic, right, and still about the Industrial division. So I was wondering if the fact that the IPO is now off the table and that you bought back Cutlite Penta means that in theory, the division is not on sale anymore. -- if it ever was, I mean, but clearly, with the IPO, there was the possibility.
Giovanni Selvetti
analystAnd the final one is quite brief. Back in February 2024, a Penta Zhejiang customer filed a lawsuit seeking reimbursement, and you set aside EUR 3.5 million for that — do you have any updates on it?
Andrea Cangioli
executiveAlright, first, sales in Europe — and I'd say outside Europe too, but in countries that aren't China and aren't Italy — are rising, and we intend for them to rise further, since we need a more balanced picture with a greater share of sales coming from markets other than China and Italy. And also because, as you pointed out, on average those carry considerably higher margins. That's likewise why our guidance points to basically better margins on sales at the very end, because we're looking at — we're guiding a slight decline in sales, but not a decline in EBIT. The second item is 5.0, and what we're seeing on that front is positive. Yes, despite the summer months, the chance to apply for the 5.0 incentives has generated some movement in order bookings in Italy, and we're far more optimistic than we were a few months back. Naturally, it's a process that takes time, since we need time to deliver the orders booked over the last weeks, but order bookings in Italy during the last weeks have been noticeably stronger than before.
Andrea Cangioli
executiveThird, we returned Cutlite to where it was for strategic reasons tied to operational independence in our subsidiaries' markets. You're familiar with how our business model has consistently sought substantial independence for our business units. We hold multiple trademarks. We have multiple brands that we coordinate in our management but that, in a sense, compete with one another, and we felt that since the requirement to have Cutlite Penta beneath Penta Laser Zhejiang existed solely because of IPO needs, our strategic position would improve by making Cutlite Penta free from — more than free, I'd say, independent of Penta Laser's control. Nothing about our objective of reorganizing and ultimately finding a route for our Industrial business — for a laser cutting business — changes because of this. Fourth point. It's the <<inaudible>> case for us. <<inaudible>> is this customer's name, and for them we built a fantastic — because it truly is a fantastic — system for cutting parts, sorting parts, and integrated automation for the factory, which is aimed at building parts for a customer that makes heavy — I'm not sure how to say this in English, it makes, like, it's a competitor of Caterpillar, John Deere, that sort of vehicle, heavy vehicles for infrastructure needs.
Andrea Cangioli
executiveThe technical appraisal of the system ought to be nearing completion. We had hoped it would wrap up a few weeks back, but we're still awaiting the final result. On the technical side, we're very confident. Our confidence is lower regarding the overall outcome of this dispute because, as I said earlier and I'll say again, the customer essentially has no work anymore. It isn't operating. That customer's market shrank, and basically they're looking for an excuse not to pay. And that's because they no longer need the system. Too bad the system is a massive custom-designed one. So we hope we can obtain satisfaction from the dispute and confirm. And also, we can gain a bit of momentum in a strategic expansion of our activities, which need to move toward supplying our customers with solutions that aren't the main standard laser cutting system but are also integrated so as to deliver a complete manufacturing solution to our customers.
Bianca Fersini-Mastelloni
unknownCarlo Maritano from Intermonte has the second question.
Carlo Maritano
analystI've got a few questions. First, on China: if I recall correctly, Q1 was roughly flat versus the prior year. What I'd like to know is how the second quarter trended, and whether the cost-base optimization measures are starting to pay off. My second question concerns current trading. You've already partly addressed Italy, where you're seeing some rebound — I'm wondering whether you're also seeing a rebound in removals, which began struggling in the latter part of last year? And my last question is about cash generation. Cash generation in Q2 was pretty strong, given that historically it's a quarter of absorption. So I'm wondering whether you've partly pulled forward the usual cash generation from the second part of the year into the first quarter — what trend do you expect for cash generation next month?
Andrea Cangioli
executiveAlright, thank you, Carlo. China — the second quarter came in soft on sales, particularly there. We've been seeing international sales trend better, yet that wasn't sufficient to reach break even during the quarter. Still, the expense-cutting effort that drove a steep drop in costs beginning in the second half of 2023 did have an effect. So although sales fell versus the same quarter in 2023, costs came down and the loss came down as well — but the quarter still showed a loss. On current trends: in medical, I think we're positioned quite well. Some uncertainty lingers in the U.S. market, which, as I said earlier, has proven very tough in this 2024 so far. We performed reasonably well, but we brought out new products. We expanded the roster of partners active in the market. So we did very significant work, yet the market isn't easy — as the quite weak results from our competitors make clear. As for hair, right now we're doing fairly well. We introduced new products. It's hard to say at this point whether we'll manage to lift our performance through year-end.
Andrea Cangioli
executiveThe positive side is that our dependence on hair removal is decreasing, and we're strengthening our position in the other application segment, as I said earlier. On cash — and on cash, I mean, I'd like to say yes, but if you look closely, we did perform well in cash generation, though you have to factor in that within the cash generation balances of the first household there are 2 significant non-recurring inflows. So I think the current cash management was good but wouldn't have produced the increase in our cash position. That said, as I explained, we're discussing a seasonal pattern in cash absorption, and we're counting on a better seasonal pattern in cash management. As a result, we expect the net financial position, in its ordinary course, to keep improving through the year.
Bianca Fersini-Mastelloni
unknownAndrea Bonfa from Banca Akros has the third question.
Andrea Bonfà
analystAndrea, I have a few questions, and some of them have already been partly answered. But if you look at the profitability by sector that you kindly published in your interim report, the industrial business is actually more profitable than last year at the divisional level, though only by a very small amount. Still, given the magnitude, the sales decline is quite a remarkable result. You have already partly explained this, but my curiosity is whether that is more related to cost reduction or more related to better mix. If you could comment further on that, I would appreciate it. And although your sales guidance is a little bit behind your initial expectation, should we expect the Medical sector to turn into positive growth for the second half of the year? Or what are your expectations there?
Andrea Cangioli
executiveThank you, Andrea. A number of elements explain why the Industrial sector turned in improved profitability during this half. We cut costs in China. We raised the share of sales coming from markets with higher margins. We sold less in Italy, where our selling effort is very aggressive. Fewer sales in China, where competitive pressure pushes sales margins down, more sales internationally, more sales in the laser marking business, which delivers better marginality than the cutting system. Those are the operational drivers. On top of that, as Enrico said during his presentation, we benefit from reimbursement for the flood damages, which lifts our P&L for the first half of 2024 and accounts for a significant portion — a not-negligible portion — of the Industrial sector's 2024 profits. As for the trend we anticipate in the Medical business, yes, we expect Medical to stay strong and to beat the 2023 revenue performance in the second half of the year. That is our expectation, and that is what underlies our guidance for the year.
Andrea Bonfà
analystI just want to clarify something. So the EUR 1.9 million in flood reimbursement was booked entirely in the Industrial division?
Andrea Cangioli
executiveYes.
Bianca Fersini-Mastelloni
unknownAnd now, once more, we have Giovanni Selvetti of Berenberg with a follow-up question.
Giovanni Selvetti
analystYeah, sorry. Could you perhaps put a number on the Q2 loss in China? And — maybe one more thing, I noticed the minority interest's weight at the bottom line was much lower, is that still because of China?
Andrea Cangioli
executiveI already responded to the second question. As for the first one, I think the figures are there in the financials. I'd rather stick to what's public and not share additional figures. My understanding is that the net profit of the Chinese companies appears in our financials. Enrico, isn't that right?
Enrico Romagnoli
executiveYes, we do.
Andrea Cangioli
executiveThat means you're able to respond to this question. While we're at it, regarding the second question — pardon me.
Giovanni Selvetti
analystMinority.
Andrea Cangioli
executiveRight. On minorities — China has minority interests that are heavy. So the less profit we generate in China, the smaller those minority interests are. Japan also carries minorities. And in Japan, we lost money during the quarter. So the only business where we hold meaningful minorities that actually improved versus 2023, I believe, is Lasit. Meanwhile, ASA, another business with minorities, in therapy, saw its income decline in 2024. So it isn't just China — Japan and ASA are also driving the drop in minority interest within early net sales. Enrico?
Enrico Romagnoli
executiveRight, the China loss was EUR 4.2 million in H1 2023, and at present it stands at a loss of EUR 2 million for H1 2024.
Andrea Cangioli
executiveThis is a net loss, not a net profit.
Enrico Romagnoli
executiveThat represents a loss overall.
Andrea Cangioli
executiveTo sum things up.
Giovanni Selvetti
analystAnd I think maybe I didn't catch what you were telling Andrea earlier — that you expect Medical revenues in the second half to come in above the second half of 2023. Medical revenue? So..
Andrea Cangioli
executiveYes. Yes… that’s what we expect, and it’s what we’ve planned for. That’s what we’re counting on. Let’s hope — we hope we can get there.
Giovanni Selvetti
analystAlright, I’m not sure — I just wanted to double-check, since the line dropped on the second.
Bianca Fersini-Mastelloni
unknownAll right, Andrea. There aren't any further questions on our list. I'd like to check with everyone attending—is there anyone else who would like to pose a question? No, we don't have any additional questions listed. I'd kindly like to open the floor. Should you have any questions you'd like to look into, please feel free to reach out to Enrico Romagnoli. He'll be glad to respond to whatever you ask. Thanks for joining this conference, and we look forward to having all of you back next time. Good afternoon, everyone.
Andrea Cangioli
executiveThanks, everyone.
Enrico Romagnoli
executiveTake care. Thanks.
Nicola Fiore
unknownTake care.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.